Full Press Release Details
BridgeBio Pharma And Sentynl Therapeutics Announce Asset Purchase Agreement For BridgeBio Pharma's NULIBRY (fosdenopterin) And Investigational Pediatric Formulation.
BBIO
BridgeBio Pharma And Sentynl Therapeutics Announce Asset Purchase Agreement For BridgeBio Pharma's NULIBRY (fosdenopterin) And Investigational Pediatric Formulation
Key Takeaway: BridgeBio Pharma And Sentynl Therapeutics Announce Asset Purchase Agreement For BridgeBio Pharma's NULIBRY (fosdenopterin) And Investigational Pediatric Formulation
Price reaction · baseline $7.51 (2022-03-07 close) · hit after-hours · 1 other BBIO headline(s) in the window, move may be shared
day 0 close · peak
+4.3%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis